Research and Markets (http://www.researchandmarkets.com/research/wzm3wx/respiratory) has announced the addition of the "Respiratory Distress Syndrome-Pipeline Insights, 2015" subscription to their offering.

This Respiratory Distress Syndrome-Pipeline Insights, 2015, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Respiratory Distress Syndrome.

This report provides information on the therapeutic development based on the Respiratory Distress Syndrome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Key Topics Covered:

  1. Respiratory Distress Syndrome Overview
  2. Respiratory Distress Syndrome Pipeline Therapeutics
  3. Respiratory Distress Syndrome Therapeutics under Development by Companies
  4. Respiratory Distress Syndrome Late Stage Products (Filed and Phase III)
  5. Comparative Analysis
  6. Respiratory Distress Syndrome Mid Clinical Stage Products (Phase II)
  7. Comparative Analysis
  8. Respiratory Distress Syndrome Early Clinical Stage Products (Phase I and IND Filed)
  9. Comparative Analysis
  10. Respiratory Distress Syndrome Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Respiratory Distress Syndrome - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Respiratory Distress Syndrome - Discontinued Products
  19. Respiratory Distress Syndrome - Dormant Products
  20. Companies Involved in Therapeutics Development for Respiratory Distress Syndrome
  21. Appendix

For more information visit http://www.researchandmarkets.com/research/wzm3wx/respiratory